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Abstract
Background: Over the last 20 years, integrated care programs for frail elderly people aimed to prevent functional
dependence and reduce hospitalization and institutionalization. However, results have been inconsistent and
merely modest. To date, evidence on the cost-effectiveness of these programs is scarce. We evaluated the cost-
effectiveness of the CareWell program, a multicomponent integrated care program for frail elderly people.
Methods: Economic evaluation from a healthcare perspective embedded in a cluster controlled trial of 12 months in
12 general practices in (the region of) Nijmegen. Two hundred and four frail elderly from 6 general practices in the
intervention group received care according to the CareWell program, consisting of multidisciplinary team meetings,
proactive care planning, case management, and medication reviews; 165 frail elderly from 6 general practices in the
control group received usual care. In cost-effectiveness analyses, we related costs to daily functioning (Katz-15 change
score i.e. follow up score minus baseline score) and quality adjusted life years (EQ-5D-3 L).
Results: Adjusted mean costs directly related to the intervention were €456 per person. Adjusted mean total costs, i.e.
intervention costs plus healthcare utilization costs, were €1583 (95% CI -4647 to 1481) higher in the intervention group
than in the control group. Incremental Net Monetary Benefits did not show significant differences between groups, but
on average tended to favour usual care.
Conclusions: The CareWell primary program was not cost-effective after 12 months. From a cost-effectiveness
perspective, widespread implementation of the program in its current form cannot be recommended.
Trial registration: The study was registered in the ClinicalTrials.govProtocol Registration System: (NCT01499797;
December 26, 2011). Retrospectively registered.
Keywords: Cost-benefit analysis, Frail elderly, Delivery of health care, Integrated, Activities of daily living, Primary health care
Background
Frail elderly account for a disproportionally large share of
healthcare costs, spending over $70,000/year in 2011 in the
United States, with particularly high expenditure on in-
patient and post-acute care [1, 2]. In the Western world,
the prevalence of frailty - a state of increased vulnerability
to adverse outcomes through a complex interplay of phys-
ical, psychological, social and environmental factors [3] –
will even increase due to population ageing, since frailty is
thought to be present in 10% of people aged ≥65 years up
to 25%–50% of people aged ≥85 years [4, 5]. Western coun-
tries are forced to adapt their healthcare policies addressing
frail elderly in order to achieve cost reductions in health
and social services and maintain financial sustainability.
Proactive integrated care programs, addressing the com-
plex and interacting healthcare and welfare needs, are
thought to have the potential to prevent adverse outcomes
and lower healthcare costs [6, 7]. However, results so far
have shown merely modest, inconsistent results regarding
their effectiveness and efficiency [8–12]. Some studies
pointed out the potential to prevent hospitalization and
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nursing home admissions [10, 11, 13], but accompanying
increases in home care and social services use might im-
pede overall cost savings [8, 10, 14]. Formal economic
evaluations of integrated programs targeting frail elderly
are scarce [15, 16]. Moreover, heterogeneity between stud-
ies regarding target population (age, low or high risk of
functional decline), context (home-, primary care- or insti-
tution based), and intervention components hinder com-
parability and generalizability. Moreover, results of
economic evaluations need to be interpreted in the light
of national contexts [17].
In the Netherlands, the Dutch Ministry of Health, Welfare
and Sports initiated the National Care for the Elderly
Program in 2008, in which over 650 organizations in health,
welfare and housing work together in eight regional net-
works led by academic medical centres to improve care for
elderly people with complex care needs. As part of this pro-
gram, we developed the CareWell primary care program that
aimed to reduce functional decline, institutionalization, and
hospitalization of community-dwelling frail elderly. Although
effectiveness of the program could not be demonstrated [18],
the program might theoretically save overall costs and, de-
pending on the trade-off between costs and effects, might be
cost-effective. Therefore, we conducted a separate economic
evaluation to answer the following research questions:
– What are the differences in health care costs between
participants receiving care according to the CareWell
primary care program and those receiving care as usual?
– Is the CareWell primary care program cost-effective
from a healthcare perspective after 12 months?
Methods
Design
This economic evaluation from a healthcare perspective
was performed alongside a cluster controlled effective-
ness study with a follow-up of 12 months. Design,
methods and outcomes of the effectiveness study have
been reported elsewhere [18].
Setting and participants
The study was conducted between September 2011 and
September 2012 in 12 general practitioner (GP) practices
in the region of Nijmegen, the Netherlands. After in-
formed consent, frail elderly aged ≥70 years were included
with the use of the EASY-Care TOS instrument [19]: First,
GPs use prior knowledge to subdivide ‘not frail’ from
‘(possibly) frail’ elders. Then, trained nurses perform a
comprehensive geriatric assessment of (possible) frail el-
ders during a home visit. Last, GPs and nurses weigh all
signs into a final frailty judgment. Exclusion criteria were
institutionalization, and/or critical or terminal illnesses.
Details on the recruitment and informed consent proce-
dures have been reported previously [18, 20].
Intervention
In brief, the CareWell primary care program consisted
of four key components: 1) multidisciplinary team
(MDT) meetings, 2) proactive care planning, 3) case
management, and 4) medication reviews.
Each practice assembled a MDT consisting of a general
practitioner (GP), practice nurse(s) and/or community
nurse(s), an elderly care physician (ECP) [21], and a social
worker with elderly care expertise. Each participant was
discussed in a MDT meeting at least half-yearly, more
often if needed. Meetings were planned every 4–8 weeks.
Tailor-made proactive care plans, based on the individual
health-related problems and goals as assessed with the
EASY-Care TOS [19], were formulated for each partici-
pant on enrolment in the program and revised after dis-
cussion in a MDT meeting at least every 6 months. A case
manager, either a nurse or social worker, was assigned to
each participant. They were responsible for care planning
and coordination, patient-support in goal setting and self-
management, and caregivers support. Last, the GP and
nurse conducted a yearly medication review in collabor-
ation with a pharmacist for each participant with poly-
pharmacy (use of ≥5 chronically prescribed drugs).
Professionals received financial reimbursement to
cover time-investment and overhead costs.
Usual care
In the Netherlands, GPs provide continuous, person-
centred care to community-dwelling frail elderly, facili-
tated by the use of high-standard electronic medical re-
cords and patient panels, defining the population under
care [22, 23]. GPs often collaborate with practice and/or
community nurses. Moreover, elderly care physicians, i.e.
medical practitioners that are specialized as primary care
experts in geriatric medicine, increasingly operate (as
consultants) in the care for community-dwelling frail
elderly [21]. However, the coordination between GPs,
other primary and specialist care providers, and home
care and community services is often perceived to be in-
sufficient, leading to a fragmented delivery of care [24].
GPs in the usual care group were explicitly asked to decline
new relevant inter professional collaborations during the
intervention period. No restrictions on pre-existing collabora-
tions between GPs and (practice) nurses were imposed.
Outcome measures
Dependence in functioning in (instrumental) activities of
daily living (measured with the Katz-15 [25] change score, i.
e. follow-up score minus baseline score) and health-related
quality of life (measured with the EuroQol five-dimensional
three-level instrument (EQ-5D-3 L) [26]) were collected at
baseline and at follow-up after 12 months by structured in-
terviews by trained nurses. The Katz-15 score ranges from
0 to 15 points with higher scores indicating more
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dependence in (instrumental) activities of daily living. The
EQ-5D-3 L instrument is a ‘preference-based’ measure of
health status [27], that defines health-related quality of life
according to five dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression) at three
levels (no problems, some problems, severe problems) [26].
In line with the guidelines of the National Care for the Eld-
erly Program, we used the modified EQ-5D+C-3 L instru-
ment that includes cognitive functioning as an additional
dimension, with a similar operationalization at three levels
[28]. To date, to the best of our knowledge, there is no vali-
dated weighting formula for the EQ-5D+C-3 L. Utilities,
reflecting the relative desirability of each health state, were
thus calculated for the EQ-5D-3 L, without the cognitive
dimension, using the Dutch tariff [29]. EQ-5D-3 L scores
range from − 0.33 to 1.00, with a higher score indicating a
higher health status. Quality Adjusted Life Years (QALYs)
were then calculated by multiplying the utilities by the
amount of time spent in a particular health state. 1 QALY
represents 1 year in perfect health [29].
Healthcare utilization costs and intervention costs
We assessed intervention costs and healthcare utilization
during the follow up period. [17] An overview of the
healthcare cost variables, prices per unit and sources are
presented in Table 1.
Intervention costs regarding time spent on team meet-
ings, care planning, case management, and medication re-
views were assessed by instructing practice and/or
community nurses and social workers to fill in monthly
time registration forms at participant level. To stimulate
uniformity in and compliance with time registrations, struc-
tured timesheets with written instructions were sent each
month as reminders. GPs and ECPs estimated their mean
time spent on the intervention per GP practice, from which
invested time per participant was calculated. Pharmacists
Table 1 Overview of the cost variables, sources, and cost prices per unit
Cost variable Source of variable Cost price per unit (in Euros)
Healthcare utilization costs:
GP carea (per contact):
Consultation Structured interview 28
Consult > 20 min Structured interview 56
Home visit Structured interview 43
Home visit > 20 min Structured interview 72
Consultation by phone Structured interview 14
Prescription refill Structured interview 14
GP care, out of office hoursb (per contact) Structured interview 101
Home care (per hour) Structured interview 35
Domestic care (per hour) Municipality registries 12,5
Hospital care, inpatient (per day) Structured interview 457
Hospital care, outpatient (per contact) Structured interview 72
Nursing home (per day) Structured interview 238
Care home (per day) Structured interview 90
Day care (per day) Welfare organization registries 45
Physiotherapy (per contact) Structured interview 36
Medicationc Electronic patient file n/a





Elderly care physicianb 103
Pharmacistb 85
Sources of cost prices per unit:
aDutch guideline for costing research[30]
bDutch Healthcare Authority
cRoyal Dutch Society for Pharmacy[31]
dCollective Agreements
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estimated a time investment of 30 min per participant per
medication review.
Healthcare utilization variables, i.e. GP care, hospital
care, institutionalization (i.e. nursing home admission,
care home admission), home care, and physiotherapy
were individually assessed at baseline and follow up
through a structured interview by the nurse. Data on do-
mestic care and day care were individually extracted
from registries from the municipality of Nijmegen and
welfare organizations. Last, data on medication costs
(both reimbursed and non-reimbursed) were individually
extracted from the electronic patient files (EPF).
Costs were calculated by multiplying volumes of care
with their corresponding unit prices. In calculating costs
of time invested by practice and/or community nurses
and social workers we used their Collective Agreements.
The thus generated hourly wages were raised with an esti-
mated 45% for employers and overhead expenses and thus
set on €30, €27, and €32 respectively [30]. We used hourly
wages of €103, €103, and €85 in calculating costs of time
invested by the GPs, ECPs, and pharmacists respectively,
according to the fixed rates of the Dutch Healthcare Au-
thority. Costs of healthcare utilization were valued accord-
ing to the Dutch manual for costing research [30]. When
no standardized unit cost prices were available, costs were
derived from the Dutch Healthcare Authority. Medication
costs were valued using prices of the Royal Dutch Society
for Pharmacy [31], using minimum cost prices. All costs
were presented in Euros, and indexed to the year 2011
using the consumer price index.
Statistical analysis
Katz-15 change scores and EQ-5D-3 L scores were ana-
lyzed using mixed model multilevel analyses, accounting
for clustering of participants within GP practices and
correcting for those variables that differed between
groups at baseline and correlated to the primary out-
come, as well as for baseline Katz-15 and EQ-5D-3 L
scores to account for regression to the mean [18]. Qual-
ity adjusted life years (QALYs) were derived from the
EQ-5D-3 L using the trapezium rule (i.e. an approxima-
tion of the area under the QALY curve). Mean health-
care utilization costs were analyzed with descriptive
statistics and compared between groups using multilevel
mixed model analyses, adjusting for clustering of partici-
pants within GP practices and for relevant covariates.
The incremental Net Monetary Benefit (iNMB) statistic
was used to evaluate cost-effectiveness [32] and conse-
quently used as the dependent variable in the mixed
model. The iNMB prevents several statistical drawbacks
of an incremental cost-effectiveness ratio and enables
the use of multilevel regression techniques including co-
variates in a convenient way [17]. It indicates the monet-
ary gains or costs of an intervention at explicit
Willingness to Pay (WTP) thresholds per gained unit of
effect. In formula: iNMB = (WTP * Δ effects) – Δ costs.
An iNMB (and 95% lower-level confidence interval)
greater than zero indicates significant cost-effectiveness
of the intervention. We used five WTP thresholds per
point improvement on the Katz-15 change score, i.e. €0,
€5000, €10,000, €15,000, and €20,000, where no refer-
ence values were readily available. Six commonly used
WTP thresholds per QALY were used: €0, €20,000,
€40,000, €60,000, €80,000, and €100,000 [33].
Results
Participants
In total, 536 participants (287 in the intervention group
resp. 249 in the control group) were included in the effect-
iveness study [18]. At baseline, participants in the inter-
vention group significantly more often lived alone, had
more health-related limitations in social functioning, more
cognitive deficits, and more social disadvantage, but
showed less complex care [18]. No significant between-
group differences in baseline Katz-15 scores and EQ-5D-
3 L scores were found. We had a loss to follow up of 28.
9% participants in the intervention group and 33.7% in
the control group, mainly due to death, institutionalization
and declined consent for follow-up (Fig. 1). Additionally,
we encountered a considerable number of missing cost
variables, mainly medication cost data due to declined
consent for use of EPF medication data and limited cover-
age of medication data in the EPFs. We adhered a
complete case analysis with regard to missing values [34].
We analyzed costs and iNMB both with and without
medication cost data, including 148 (51.6%) resp. 182 (63.
4%) participants in the intervention group and 103 (41.
3%) resp. 146 (58.6%) participants in the control group
(Fig. 1), and considered the analyses including medication
costs as the primary analysis. Participants included in the
economic evaluation had a lower frailty index. This frailty
index was calculated based on the accumulation of deficits
in health (symptoms, morbidities, and/or functional abil-
ities), and was used as an extra indicator of frailty next to
the EasyCare-TOS [28]. It theoretically ranges from 0 (no
indication of frailty) to 1 (extreme frailty), though frailty
index scores in similar studies typically culminate at 0.7.
Therefore, in addition to the covariates included in the ef-
fectiveness analysis, the frailty index was included as a co-
variate in this economic evaluation.
Outcome measures
At 12 months, we found no significant differences in
functional dependence (adjusted mean difference of 0.
37, 95% CI -0.1 to 0.8) nor QALYs (adjusted mean differ-
ence of − 0.031, 95% CI -0.1 to 0.0) between the inter-
vention and control group, but the control group did
show less functional decline (Table 2) [18].
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Healthcare utilization costs and intervention costs
Mean intervention costs, adjusted for clustering and rele-
vant covariates, were €456 (95% CI -512 to − 398). In the
intervention group, mean total costs, i.e. intervention
costs plus healthcare utilization costs, adjusted for cluster-
ing and relevant covariates, were €1583 (95% CI -4647 to
1481) higher than in the control group. Mean adjusted
healthcare utilization costs, i.e. without the intervention
costs, were €1143 (95% CI -4198 to 1912) higher in the
intervention group. Of the healthcare utilization variables,
only medication costs differed significantly, although
mean costs of hospitalization, institutionalization, home
care and physiotherapy in the intervention group
exceeded those in the control group (Table 2).
Economic analysis
Figure 2 shows the iNMBs. It can be noticed that generally
these iNMBs are negative, meaning that the intervention
does not provide value for money compared to usual care,
although the results are not significant. Sensitivity analysis,
excluding medication costs, underlined these results.
Discussion
In this cluster controlled study with a follow up of
12 months, healthcare utilization costs and cost-
effectiveness of the CareWell primary care program was
compared to usual care. Earlier, effectiveness of the Care-
Well program on daily functioning and quality of life could
not be demonstrated [18]. In this study, we found no statis-
tically significant differences between groups in total costs
and healthcare utilization costs, with the exception of
higher medication costs in the intervention group. More-
over, cost-effectiveness analyses showed no significant dif-
ferences between groups, but tended to favour usual care.
There are some possible explanations for the absence
of cost-effectiveness. First, there is still a lively debate on
the concept of frailty and the right timing of interven-
tions [35, 36]. Possibly, the targeted population was too
heterogeneous or, in part, too frail to respond to the
intervention. Second, the Katz-15 index, measuring daily
functioning, might be too restricted to capture the ef-
fects of our heterogeneous intervention. Possibly, more
person- or goal centred outcomes, e.g. goal-attainment
scaling, might suit better [37]. Moreover, the sensitivity
Fig. 1 Flow diagram of participants
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to change of the EQ-5D-3 L in frail elders might have
been (too) low [38]. The concept of ‘capability wellbeing’
has recently been suggested as an alternative, more sen-
sitive measure [33]. However, further work on the valid-
ity and value of these capability indices in economic
evaluations is needed [33, 39]. Third, it is likely that
more profound effects of the intervention only become
apparent after a longer follow up period that exceeds the
time needed for implementation, individual and
organizational learning effects, and efficient multidiscip-
linary collaboration [40, 41]. This lag-time in effective-
ness is presumed to be even more important in complex
interventions like our program [40]. Awareness to these
short-run inefficiencies that might have resulted from
the time limits set by the National Care for the Elderly
Program is needed. Last, the selection of motivated pro-
fessionals in the intervention group might have limited
the room for improvement in the delivered care and
possibly led to higher costs due to more proactive care,
irrespective of the CareWell program. The overall in-
creased awareness to the health care needs of frail eld-
erly in Western countries in the last two decades
together with the Dutch high-quality primary care might
have further reduced the contrasts between the Care-
Well program and usual care. Possibly, our program
would show clearer effectiveness in less well managed
healthcare settings [12].
Our results are in line with comparable integrated care
programs aimed at frail elderly, performed in other con-
texts [14, 42]. More recently, three cost-effectiveness stud-
ies of integrated care programs from the National Care for
the Elderly Program demonstrated no effects on function-
ing nor quality of life, at unchanged or higher total costs
mainly due to increased GP care and intervention costs
without (expected) decreases in hospital and long-term
care costs, after 12–24 months [43–45]. However, Van
Leeuwen et al. did find increasing effects at lower costs
compared to usual care in the last 18–24 months of follow
up [45]. Previously, Counsell et al. demonstrated similar
decreased costs in their third year of follow up, mainly
through a shift away from emergency and hospital services
towards more-desirable chronic and preventive care
expenditures [14]. This supports our assumption of a lag-
time in effectiveness. The results of the cost-utility
analyses of the recent other Dutch studies, finding low
probabilities of the intervention increasing QALYs at
lower costs, correspond with our results [45, 46].
However, only Van Leeuwen et al. performed a formal
cost-effectiveness analysis [45]. Like us, they found low
probabilities of the intervention being cost-effective.
Table 2 Costs of care in intervention and control groups 0–12 months (in Euros)
Intervention group Control group Adjusted mean differenceb (95% CI) P value
Unadjusted meana SEd Unadjusted meana SEd
Outcome:
Katz-15 change score1 0.80 0.13 0.50 0.16 0.37 (−0.10 to 0.80) .10
QALY2 0.60 0.02 0.60 0.02 −0.03 (− 0.10 to 0.00) .37
Intervention costs: 456 14 0 0 − 455 (− 512 to − 398) <.001
Healthcare utilization costs, total: 10,125 983 8114 845 −1143 (− 4198 to 1912) .46
GP care 163 13 169 18
GP care, out of office hours 40 11 36 7
Hospital care, inpatient 1557 510 1225 248
Hospital care, outpatient 239 24 304 40
Nursing home 943 399 198 118
Care home 416 218 161 76
Day care 422 102 342 101
Home care 3712 423 2787 412
Domestic care 1472 91 1417 113
Physiotherapy 988 309 485 87
Medication 1617 296 978 126
Total costsc 10,576 983 8114 845 −1583 (− 4647 to 1481) .31
1Katz-15 index (range 0 to 15); higher score indicates more functional dependence in (instrumental) activities of daily living
2Quality Adjusted Life Years (QALY), as derived from the EQ-5D-3 L.
aUnadjusted means, analyzed with descriptive techniques
bMultilevel mixed model analyses, accounting for clustering and covariates
cTotal costs = intervention costs plus healthcare utilization costs
dSE standard error
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This study has several strengths. First, we used a com-
prehensive approach to costing, including a wide variety
of cost variables that were assessed at participant level,
thus enhancing internal validity. Next, robust multilevel
techniques were used in analyzing both differences in
costs and net monetary benefits. Last, since we used
only a limited number of exclusion criteria and included
participants from heterogeneous GP practices, our re-
sults should be generalizable to the population of frail
elders in the Netherlands and comparable high-quality
primary care settings.
We also should consider some limitations. First, we were
unable to include informal care costs, since informal care-
givers’ willingness to participate was low and differed be-
tween groups. We were therefore not able to adhere to the
societal perspective, as announced in our study protocol
[20], but had to switch to a healthcare perspective. Since
prior studies show contrasting results on the impact of
Fig. 2 Incremental net monetary benefits (in Euros) against WTP for Katz-15 change score* and QALY. Upper panels show the incremental net
monetary benefits (in formula: iNMB = (WTP * Δ effects) – Δ costs) against WTP for Katz-15 change scores; lower panels show iNMBs against WTP
for QALY. All iNMBs are negative, i.e. the intervention does not provide value for money compared to usual care (not significant). Sensitivity
analyses, excluding medication costs, underline the results (right panels)WTP =Willingness to Pay. QALY = Quality Adjusted Life Year, derived from
the EQ-5D-3 L, based on the Dutch tariff [29] using the trapezium rule.* Improvement on the Katz-15 change score is indicated by a lower score,
meaning less functional decline regarding (instrumental) activities of daily living
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informal care on total costs, the impact of this switch on
our results is unclear [42, 45]. Next, since the extraction of
data on healthcare use from external sources like healthcare
insurance companies, as originally planned in the study de-
sign, was not possible, we had to collect these data through
participants’ retrospective self-report. This could have led
to recall bias. Different studies showed self-report after
12 months to be an appropriate, reasonably accurate
method for obtaining a wide range of healthcare utilization
data in elderly people [47, 48]. More salient events in gen-
eral suffer less from memory decay and thus recall bias
[49]. Seidl et al. for example found the recall bias of hospital
admissions of elderly people not to be influenced by apply-
ing various recall periods, although the probability of cor-
rectly self-reporting a single event was higher using a
shorter recall period [48]. However, less salient events such
as GP contacts could lead to both under- and over-
reporting, and show less accuracy in self-report [49, 50].
Also, time registrations used to calculate intervention costs
might be biased due to inaccuracies. However, we have no
reason to assume unequal distributions of these potential
biases between the groups. Last, we had to deal with a con-
siderable number of missing medication cost data that had
to be considered missing not at random. However, our add-
itional sensitivity analysis without medication costs did not
reveal other results.
Conclusions
After 12 months follow-up, no net monetary benefit of the
CareWell program over usual care could be demonstrated.
This study adds to the currently scarce body of evidence
regarding cost-effectiveness of integrated care programs
targeting frail elderly. Future economic evaluations should
account for pitfalls in their design with respect to the tar-
get population, outcome measures used, and adequate
follow-up period. From a cost-effectiveness perspective,
the CareWell primary program in its current form is not
suited for widespread implementation.
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